Observational studyPloS one2020

Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.

Carolina Vázquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.